vimarsana.com
Home
Live Updates
This Is Why Ocugen Crashed Despite Apparent Good News : vima
This Is Why Ocugen Crashed Despite Apparent Good News : vima
This Is Why Ocugen Crashed Despite Apparent Good News
This Is Why Ocugen Crashed Despite Apparent Good News
InvestorPlace
5/10/2021
Ocugen (NASDAQ:
OCGN) stock was a late entrant into the Covid-19 vaccine race. OCGN stock traded for less than $1 per share through December 2020. Then, however, it announced a transformative deal with India’s Bharat Biotech, and shares popped as much as 3,000% since then.
© Provided by InvestorPlace
The concept image of a vaccine passport with a needle and map.
As recently as a week ago, traders were rushing to buy OCGN stock; shares doubled in late April and hit $16 at their recent peak in the first days of May.
Since then, however, Ocugen shares lost nearly half their value in a few days of frenzied selling. What explains Ocugen’s sudden rise and equally speedy fall?
Related Keywords
South Africa ,
India ,
United States ,
United Kingdom ,
Israel ,
Seychelles ,
Brazil ,
South African ,
American ,
Bharat ,
,
Shutterstock The ,
Bharat Biotech ,
Investorplace The ,
Diabetic Macular Edema ,
Diabetic Retinopathy ,
Wet Age Related Macular Degeneration ,
இந்தியா ,
ஒன்றுபட்டது மாநிலங்களில் ,
ஒன்றுபட்டது கிஂக்டம் ,
இஸ்ரேல் ,
சீஷெல்ஸ் ,
பிரேசில் ,
அமெரிக்கன் ,
பாரத் ,
பாரத் பயோடெக் ,
நீரிழிவு மாகுலர் எடிமா ,
நீரிழிவு ரெட்டினோபதி ,
ஈரமான வாழ்நாள் தொடர்புடையது மாகுலர் சீரழிவு ,